0001209191-21-056060.txt : 20210914
0001209191-21-056060.hdr.sgml : 20210914
20210914193111
ACCESSION NUMBER: 0001209191-21-056060
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210407
FILED AS OF DATE: 20210914
DATE AS OF CHANGE: 20210914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Renaud Ronald C JR
CENTRAL INDEX KEY: 0001354434
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38550
FILM NUMBER: 211253774
MAIL ADDRESS:
STREET 1: C/O IDENIX PHARMACEUTICALS, INC.
STREET 2: 60 HAMPSHIRE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Translate Bio, Inc.
CENTRAL INDEX KEY: 0001693415
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 611807780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-945-7361
MAIL ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: RaNA Therapeutics, Inc.
DATE OF NAME CHANGE: 20161228
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2021-04-07
2021-04-09
0
0001693415
Translate Bio, Inc.
TBIO
0001354434
Renaud Ronald C JR
C/O TRANSLATE BIO, INC.
29 HARTWELL AVE
LEXINGTON
MA
02421
1
1
0
0
Chief Executive Officer
Common Stock
2021-04-07
4
M
0
9026
7.39
A
503231
D
Common Stock
409913
I
By Ronald Renaud 2014 Irrevocable Family Trust
Common Stock
40909
I
By Ronald C. Renaud, Jr. Trust - 2007
Stock Option (right to buy)
7.39
2021-04-07
4
M
0
9026
0.00
D
2027-12-21
Common Stock
9026
1071009
D
The original Form 4 filed on April 9, 2021 inadvertently reported the incorrect number of securities beneficially owned following the reported transaction by an additional 90 shares. The original Form 4 filed on April 9, 2021 stated that 503,321 shares were owned after the transaction. The correct number of shares is 503,231. This amendment is being filed solely to correct the number of securities beneficially owned.
This option was granted on December 22, 2017. The shares underlying the option vested over four years in equal monthly installments through March 9, 2021.
/s/ Paul Burgess, as attorney-in-fact for Ronald C. Renaud, Jr.
2021-09-14